Sanofi Pasteur Announces FDA Approval of Menactra Meningococcal Conjugate Vaccine Indication for Infants (SNY)

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group SNY, announced today that the U.S. Food and Drug Administration has granted licensure to expand the indication for its meningococcal conjugate vaccine, Menactra®, to include a two-dose schedule for infants and children 9 months through 23 months of age. This is the first U.S. approval of a meningococcal vaccine for this age group.